In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis
Abstract Despite the efficacy of natalizumab, which targets the integrin VLA-4, in treating multiple sclerosis (MS), approximately 35% patients with MS present evidence of disease activity two years after treatment initiation. Individual heterogeneity of leukocyte response to VLA-4 on natalizumab-me...
Saved in:
| Main Authors: | Beatriz Chaves, Juan Carlo Santos e Silva, Helder Nakaya, Nicolas Socquet-Juglard, Florence Bucciarelli, Guilhèn Prunier, Matheus V. Almeida, Claire Lacouture, Saniya Kari, Anne L. Astier, Marco A. Medeiros, João H. M. Silva, Roland Liblau, Vinicius Cotta-de-Almeida, Loïc Dupré |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-60224-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Natalizumab treatment for multiple sclerosis
by: Maria Lucia Brito Ferreira
Published: (2014-12-01) -
Natalizumab-associated progressive multifocal leukoencephalopathy
by: Trevor Glenn, et al.
Published: (2025-06-01) -
Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
by: Molly R Perkins, et al.
Published: (2012-01-01) -
Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
by: BL Johnston, et al.
Published: (2006-01-01) -
A Case of Drug-Induced Liver Injury Secondary to Natalizumab
by: Phillip P. Santoiemma, et al.
Published: (2020-01-01)